Intellia Therapeutics, a leading biotechnology company, announced that its CRISPR-based treatment for a rare swelling ...

A phase 3 trial of Intellia Therapeutics’ in vivo gene-editing therapy lonvoguran ziclumeran (lonvo-z) has hit its primary ...

Intellia Therapeutics (NTLA) shares charged up on April 27 after the company announced landmark Phase 3 results for its ...

JMIR Publications today featured two new stories in its News and Perspectives section, highlighting a shift toward proactive, ...

Intellia’s in vivo CRISPR gene therapy for hereditary angioedema cut attack rates by 87% in a Phase III trial, prompting a rolling FDA submission. Novartis secured EU approval for the first oral ...

Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...

In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for ...

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a ...

CRISPR Therapeutics' recent in vivo CTX310 data validates its technology, marking a fundamental shift and supporting a rating upgrade from Sell to Hold. CASGEVY sales are growing but remain ...

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced ...

We'll know more about the company's medium-term prospects by the end of the year.